BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 29674439)

  • 1. Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience.
    Jin Z; Sanhueza CT; Johnson B; Nagorney DM; Larson DW; Mara KC; Harmsen WC; Smyrk TC; Grothey A; Hubbard JM
    Oncologist; 2018 Sep; 23(9):1083-1091. PubMed ID: 29674439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Metastasectomy in the Multimodality Approach for
    Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
    Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
    Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
    Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry.
    Chong LC; Townsend AR; Young J; Roy A; Piantadosi C; Hardingham JE; Roder D; Karapetis C; Padbury R; Maddern G; Moore J; Price TJ
    Target Oncol; 2019 Feb; 14(1):85-91. PubMed ID: 30659494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
    Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
    J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
    [No Abstract]   [Full Text] [Related]  

  • 7. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
    Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
    Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
    Goldstein J; Tran B; Ensor J; Gibbs P; Wong HL; Wong SF; Vilar E; Tie J; Broaddus R; Kopetz S; Desai J; Overman MJ
    Ann Oncol; 2014 May; 25(5):1032-8. PubMed ID: 24585723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
    Tougeron D; Sueur B; Zaanan A; de la Fouchardiére C; Sefrioui D; Lecomte T; Aparicio T; Des Guetz G; Artru P; Hautefeuille V; Coriat R; Moulin V; Locher C; Touchefeu Y; Lecaille C; Goujon G; Ferru A; Evrard C; Chautard R; Gentilhomme L; Vernerey D; Taieb J; André T; Henriques J; Cohen R;
    Int J Cancer; 2020 Jul; 147(1):285-296. PubMed ID: 31970760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency.
    Polom K; Böger C; Smyth E; Marrelli D; Behrens HM; Marano L; Becker T; Lordick F; Röcken C; Roviello F
    Eur J Surg Oncol; 2018 May; 44(5):626-631. PubMed ID: 29545085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellite instability and sensitivity to fluoropyrimidine and oxaliplatin containing first-line chemotherapy in metastatic colorectal cancer.
    Liu J; Wang B; Fang W
    Eur J Hosp Pharm; 2020 Sep; 27(5):267-270. PubMed ID: 32839257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of clinicopathological features and prognosis of sporadic synchronous multiple primary colorectal cancers].
    Qin ZF; Xu GH; Zhou SQ; Zheng PW; Zhu YP; Ju HX; Li DC; Ma DN
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1171-1178. PubMed ID: 38110279
    [No Abstract]   [Full Text] [Related]  

  • 13. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
    Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
    Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Mismatch Repair Status Between Primary and Matched Metastatic Sites in Patients With Colorectal Cancer.
    He WZ; Hu WM; Wang F; Rong YM; Yang L; Xie QK; Yang YZ; Jiang C; Qiu HJ; Lu JB; Zhang B; Ding PR; Xia XJ; Shao JY; Xia LP
    J Natl Compr Canc Netw; 2019 Oct; 17(10):1174-1183. PubMed ID: 31590148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials.
    Noepel-Duennebacke S; Juette H; Schulmann K; Graeven U; Porschen R; Stoehlmacher J; Hegewisch-Becker S; Raulf A; Arnold D; Reinacher-Schick A; Tannapfel A
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3063-3072. PubMed ID: 33675399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab.
    Saberzadeh-Ardestani B; Jones JC; Hubbard JM; McWilliams RR; Halfdanarson TR; Shi Q; Sonbol MB; Ticku J; Jin Z; Sinicrope FA
    JAMA Netw Open; 2023 Feb; 6(2):e230400. PubMed ID: 36811859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
    Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
    Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
    Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMAST is associated with a poor prognosis in microsatellite instable metastatic colorectal cancer.
    Venderbosch S; van Lent-van Vliet S; de Haan AF; Ligtenberg MJ; Goossens M; Punt CJ; Koopman M; Nagtegaal ID
    PLoS One; 2015; 10(4):e0124538. PubMed ID: 25884216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between genetic alterations and prognosis in sporadic colorectal cancer.
    Chang SC; Lin JK; Yang SH; Wang HS; Li AF; Chi CW
    Int J Cancer; 2006 Apr; 118(7):1721-7. PubMed ID: 16231316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.